Juventas Therapeutics Closes $22.2 Million Venture Capital Round
Cleveland, OH--Continuing its success in growing its strategic investor base, Juventas Therapeutics
has closed a $22.2 million Series C venture capital investment that includes new investors Takeda Pharmaceuticals, Venture Investors, Tri-State Growth Fund, and Glengary Ventures. The round was led by previous investors Triathlon Medical Ventures and New Science Ventures, with participation from continuing investors Early Stage Partners, Fletcher Spaght Ventures, and Reservoir Venture Partners.
The funding will enable the company to simultaneously conduct two Phase II clinical trials, one for chronic heart failure and one for critical limb ischemia. Takeda's investment is financial only, with no special terms or strategic interests. Read more
Find Out More About ESP
Mike Bunker led the Early Stage Partners venture capital investment in Juventas Therapeutics